alert-en Icon

Winter Weather Alert: Some locations, classes, and events may have adjusted hours or closures. Please call ahead for updates. Stay safe!

Leukemia

 

Leukemia Oncology Research Studies

BLAST MRD CML 1 Trial: BLockade of PD-1 Added to Standard Therapy to Target Measurable Residual Disease (MRD) in Chronic Myeloid Leukemia (CML)- A Phase II Study of Adding the Anti-PD-1 Pembrolizumab to Tyrosine Kinase Inhibitors in Patients with CML and Persistently Detectable MRD
EA9171

 

Contact Us

Give us a call to learn more about our oncology research studies.